<DOC>
	<DOCNO>NCT01636843</DOCNO>
	<brief_summary>This trial conduct Europe , North America South America . The aim trial investigate clinical efficacy NNC0109-0012 , human monoclonal antibody , compare placebo administer weekly repeat subcutaneous ( skin ) injection patient active rheumatoid arthritis ( RA ) inadequate response methotrexate ( MTX ) stable background MTX therapy .</brief_summary>
	<brief_title>A Trial NNC0109-0012 , Anti-IL-20 Biologic , Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Informed consent must obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial A documented diagnosis RA least 6 month prior screen visit , accord American College Rheumatology ( EULAR/ACR 2010 criterion ) standard criterion ( ACR 1987 ) diagnosis make earlier 2010 Active RA , characterise : a. 5 tender 5 swollen joint base 28 joint count b. Creactive protein ( CRP ) equal 1.0 mg/dL ( 10 mg/L ) Patients methotrexate without hydroxychloroquine/chloroquine : a. Methotrexate treatment ( equal 15.0 mg/week ) least 16 week , ( equal 15.0 mg/week equal 25 mg/week ) least 8 week prior screen . Patient MTX low 10 mg/week due MTX intolerance b. Hydroxychloroquine ( 200400 mg/day per o , oral dosing ( p.o . ) ) chloroquine ( 250500 mg/day p.o . ) treatment least 8 week prior screen visit Patients arthritis due autoimmune disease RA Any active ongoing bacterial infection within 4 week prior screen visit , unless treat resolved appropriate therapy history recurrent infection condition predispose chronic infection ( e.g. , bronchiectasis , chronic osteomyelitis ) History severe , systemic viral fungal infection within past 6 month prior screen visit , unless treat and/or resolve appropriate therapy Patients active malignancy within previous 5 year exception adequately treat cured basal squamous cell carcinoma skin cervical carcinoma situ occur 12 month prior screen visit Females childbearing potential pregnant breast feed intend become pregnant Any disease clinically significant abnormality laboratory parameter , accord Investigator , might compromise safety patient , interfere participation trial compromise trial objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>